PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30429794-9 2018 Mechanistically, nicotine exposure enhanced expression of MMP-2/-9 and elastolytic activity in both aortic segments. Nicotine 17-25 matrix metallopeptidase 2 Mus musculus 58-66 30585623-4 2018 Nicotine also increased alpha1nAChR, calpain-1, matrix metalloproteinase-2 (MMP-2), and MMP-9 expression in the aortic tissue. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 48-74 30585623-4 2018 Nicotine also increased alpha1nAChR, calpain-1, matrix metalloproteinase-2 (MMP-2), and MMP-9 expression in the aortic tissue. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 76-81 30585623-6 2018 In vitro, nicotine-induced alpha1nAChR, calpain-1, MMP-2, and MMP-9 expression in mouse vascular smooth muscle cells (MOVAS) and macrophages (RAW264.7), and enhanced the migration and proliferation of these cells. Nicotine 10-18 matrix metallopeptidase 2 Mus musculus 51-56 30585623-9 2018 The effect of nicotine on atherogenesis may be mediated by alpha1nAChR-induced activation of the calpain-1/MMP-2/MMP-9 signaling pathway. Nicotine 14-22 matrix metallopeptidase 2 Mus musculus 107-112 31735744-5 2019 Nicotine reportedly increases the occurrence of abdominal aortic aneurysms by activating endothelin-1 (ET-1), angiotensinogen and the angiotensin II type 1 (AT1) receptor, leading to an increase in neutrophil elastase, oxidative stress, and matrix metalloproteinase (MMP)-2 expression, which causes vascular wall weakness and damage. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 241-273 31735744-7 2019 Additionally, isoflavone suppressed elastic fiber destruction and decreased areas positive for MMP-2, neutrophil elastase, and malondialdehyde in the vascular wall of nicotine-administered mice. Nicotine 167-175 matrix metallopeptidase 2 Mus musculus 95-100 29348704-8 2017 Furthermore, nicotine-induced secretions of MMP-2, MMP-9, MCP-1, and RANTES were remarkably downregulated. Nicotine 13-21 matrix metallopeptidase 2 Mus musculus 44-49 29348704-5 2017 Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES). Nicotine 98-106 matrix metallopeptidase 2 Mus musculus 155-160 29348704-6 2017 Similarly, nicotine treatment also increased phosphorylation of c-Jun and expressions of MMP-2, MMP-9, MCP-1, and RANTES in MOVAS cells. Nicotine 11-19 matrix metallopeptidase 2 Mus musculus 89-94 25381636-0 2015 Nicotine-induced upregulation of VCAM-1, MMP-2, and MMP-9 through the alpha7-nAChR-JNK pathway in RAW264.7 and MOVAS cells. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 41-46 27688602-8 2016 In conclusion, SP600125 attenuates nicotine plus AngII-induced AAA formation likely by inhibiting MMP-2, MMP-9, MCP-1, and RANTES. Nicotine 35-43 matrix metallopeptidase 2 Mus musculus 98-103 25381636-6 2015 In conclusion, nicotine-induced VCAM-1, MMP-2, and MMP-9 expressions occur in a dose-dependent fashion in both of the cell lines tested. Nicotine 15-23 matrix metallopeptidase 2 Mus musculus 40-45 25381636-7 2015 Furthermore, the nicotine exposure equivalent to plasma levels found in regular smokers can augment VCAM-1, MMP-2, and MMP-9 expressions through the alpha7-nAChR-JNK pathway. Nicotine 17-25 matrix metallopeptidase 2 Mus musculus 108-113 25381636-2 2015 In the present experiment, both the RAW264.7 and MOVAS cell lines were employed to examine the nicotine-induced modulation of VCAM-1, MMP-2, and MMP-9 expressions in macrophages and vascular smooth muscle cells. Nicotine 95-103 matrix metallopeptidase 2 Mus musculus 134-139 25381636-3 2015 Our results showed that nicotine concentrations of both 0.5 and 5 ng/ml induced VCAM-1, MMP-2, and MMP-9 upregulation, while a concentration of 50 ng/ml had a slight inhibitory effect and a concentration of 500 ng/ml showed a significant inhibitory effect. Nicotine 24-32 matrix metallopeptidase 2 Mus musculus 88-93 25381636-4 2015 When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect. Nicotine 133-141 matrix metallopeptidase 2 Mus musculus 174-179 20448088-8 2010 Expression of MMP2 and MMP9 in nicotine-treated RPE cells was decreased. Nicotine 31-39 matrix metallopeptidase 2 Mus musculus 14-18 23959951-6 2013 Activity levels of matrix metalloproteinase-2 mirrored these changes and demonstrated clear additivity between nicotine and Ang II. Nicotine 111-119 matrix metallopeptidase 2 Mus musculus 19-45 22561688-6 2012 Mechanistically, we found that both nicotine and AngII activated AMPK-alpha2 in cultured vascular smooth muscle cells (VSMCs), resulting in the phosphorylation of activator protein 2alpha (AP-2alpha) and consequent matrix metallopeptidase 2 (MMP2) gene expression. Nicotine 36-44 matrix metallopeptidase 2 Mus musculus 215-240 22561688-6 2012 Mechanistically, we found that both nicotine and AngII activated AMPK-alpha2 in cultured vascular smooth muscle cells (VSMCs), resulting in the phosphorylation of activator protein 2alpha (AP-2alpha) and consequent matrix metallopeptidase 2 (MMP2) gene expression. Nicotine 36-44 matrix metallopeptidase 2 Mus musculus 242-246 22561688-7 2012 We conclude that smoking (through nicotine) instigates AAA through AMPK-alpha2-mediated AP-2alpha-dependent MMP2 expression in VSMCs. Nicotine 34-42 matrix metallopeptidase 2 Mus musculus 108-112 14691189-11 2004 Nicotine also reversed VEGF-induced suppression of MMP-2 activity. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 51-56 34142887-9 2021 In vitro, 11,12-EET treatment attenuated nicotine-induced MMP2 upregulation via SIRT1-mediated YAP deacetylation. Nicotine 41-49 matrix metallopeptidase 2 Mus musculus 58-62